We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+17.44%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$91.5M
AUM Growth
-$12.2M
Cap. Flow
-$8.98M
Cap. Flow %
-9.81%
Top 10 Hldgs %
97.92%
Holding
43
New
3
Increased
7
Reduced
4
Closed
26

Top Buys

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$8.44M
2
KALA icon
KALA BIO
KALA
+$2.25M
3
CCAP icon
Crescent Capital BDC
CCAP
+$475K
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$334K
5
FSK icon
FS KKR Capital
FSK
+$314K

Top Sells

Rank Stock Value
1
ABDC
Alcentra Capital Corp
ABDC
+$9.1M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$4.51M
3
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$1.2M
4
CDLX icon
Cardlytics
CDLX
+$352K
5
ASMB icon
Assembly Biosciences
ASMB
+$340K

Sector Composition

Rank Sector Weight
1 Healthcare 96.76%
2 Financials 0.92%
3 Materials 0.15%
4 Real Estate 0%
5 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
1
DELISTED
Molecular Templates, Inc.
MTEM
$28M 30.63%
140,533
+1,000
+0.7% +$219K
KALA icon
2
KALA BIO
KALA
$11.8M
$16.1M 17.64%
735
+141
+24% +$2.25M
STSA
3
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$13M 14.26%
606,320
-52,932
-8% -$1.2M
SBBP
4
DELISTED
Strongbridge Biopharma plc.
SBBP
$12.5M 13.66%
6,612,065
– –
SRRA
5
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$6.32M 6.91%
+643,959
New +$8.44M
SCYX icon
6
SCYNEXIS
SCYX
$37M
$6.2M 6.78%
99,201
– –
VIRX
7
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$3.38M 3.69%
232,426
– –
GARS
8
DELISTED
Garrison Capital Inc.
GARS
$1.98M 2.16%
1,164,061
-59,035
-5% -$302K
LITS
9
Lite Strategy Inc
LITS
$33.6M
$1.43M 1.56%
44,278
+2,000
+5% +$80K
CTIC
10
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$567K 0.62%
616,695
+291,085
+89% +$334K
EIGR
11
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$555K 0.61%
2,721
+651
+31% +$208K
FSK icon
12
FS KKR Capital
FSK
$2.98B
$511K 0.56%
42,583
+14,670
+53% +$314K
CCAP icon
13
Crescent Capital BDC
CCAP
$399M
$332K 0.36%
+34,405
New +$475K
KURA icon
14
Kura Oncology
KURA
$922M
$222K 0.24%
22,302
+7
+0% +$80
CLMT icon
15
Calumet Specialty Products
CLMT
$3.63B
$138K 0.15%
131,204
-38,945
-23% -$132K
ADXN
16
Addex Therapeutics
ADXN
$115K 0.13%
+871
New +$152K
CBIO
17
Crescent Biopharma
CBIO
$602M
$34K 0.04%
151
-106
-41% -$40.5K
AMT icon
18
American Tower
AMT
$77.7B
– –
-1,214
Closed -$279K
ASMB icon
19
Assembly Biosciences
ASMB
$506M
– –
-1,385
Closed -$340K
C icon
20
Citigroup
C
$222B
– –
-3,111
Closed -$249K
CDLX icon
21
Cardlytics
CDLX
$21M
– –
-559
Closed -$352K
CHTR icon
22
Charter Communications
CHTR
$14.7B
– –
-638
Closed -$309K
CVNA icon
23
Carvana
CVNA
$43.3B
– –
-13,850
Closed -$255K
GB
24
DELISTED
Global Blue Group Holding
GB
– –
-25,569
Closed -$263K
GM icon
25
General Motors
GM
$74.7B
– –
-5,563
Closed -$204K
1
2

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q1 2020 Portfolio in Review

As of Q1 2020, Caxton Corporation held 43 positions worth $91.5M, down 12% from $104M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Caxton Corporation withdrew a net $8.98M in Q1 2020, closing 26 positions and reducing 4 holdings. Its most notable exit was Alcentra Capital Corp, an estimated $9.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 73% a quarter earlier, followed by Financials and Materials.

Against the trend, Caxton Corporation opened a new position in Sierra Oncology, Inc. Common Stock worth $6.32M.

  • Caxton Corporation's largest Q1 2020 buy was Sierra Oncology, Inc. Common Stock: 643,959 shares worth $6.32M.
  • Caxton Corporation added most to KALA BIO in Q1 2020, an estimated $2.25M increase.
  • Caxton Corporation's biggest Q1 2020 reduction was Satsuma Pharmaceuticals, Inc. Common Stock, cutting an estimated $1.2M.
  • Caxton Corporation fully exited Alcentra Capital Corp in Q1 2020, selling an estimated $9.1M.
  • Caxton Corporation's ten largest holdings make up 98% of its $91.5M portfolio in Q1 2020.
  • Caxton Corporation opened 3 new positions and closed 26 in Q1 2020.
  • Caxton Corporation's portfolio value fell 12% quarter-over-quarter to $91.5M.

Based on Caxton Corporation's 13F filing for Q1 2020, filed 15 May 2020.